Uniphar Plc · EURONEXT:UPR
Uniphar — H1 2024 Earnings Presentation
37 slides from Uniphar's earnings presentation, Sep 3, 2024
Slide 1: Enabling Healthcare: H1 24 Interim Results Presentation
Enabling Healthcare H1 24 Interim Results Presentation
Slide 2: Important Notice
This presentation has been prepared solely in connection with the financial results of Uniphar plc (the "Company") for the period ended 30 June 2024 and should be read in conjunction with the announcement of the interim results of the Company for the period ended 30 June 2024, released 03 September
Slide 3: Agenda
Agenda 01 Overview & Highlights Presenters 02 Divisional Review Ger Rabbette 03 Financial Review Chief Executive Officer 04 Capital Allocation Tim Dolphin & Investment Case Chief Financial Officer 05 Q&A 3
Slide 4: Overview & Highlights
Overview & Highlights 4
Slide 5: Uniphar at a glance
Uniphar at a glance Divisional Gross Profit A diversified international Organic gross profit growth across all divisions healthcare services provider Supporting 200 multinational H1’24 Organic 200 pharmaceutical and Medtech manufacturers €’m Growth % Growth % across three divisions Uniphar SC+R 95.3
Slide 6: Financial Highlights
Financial Highlights Continued growth across all divisions Delivering Strong financial Robust capital Investment in M&A an Medium-term on expectations performance structure strategic capex important part of target of €200m projects strategy EBITDA • Leveraging scale and • Growth in gross • Adjusted
Slide 7: Sustainability Highlights
Sustainability Highlights Sustainability is at the core of what we do and is deeply embedded in our business strategy Continued progress against our five pillars 1 2 3 4 5 People Community Environment Governance Quality Business Solutions & Workplace Involvement & Sustainability & Compliance & Innov
Slide 8: Divisional Review
Divisional Review 8
Slide 9: Divisional strategic objectives
Divisional strategic objectives Organic Gross Profit Growth Low-Single Digit High-Single Digit Double Digit Target Gross Profit €95.3m €53.5m €57.9m H1’2024 Gross Profit 10.7% 40.4% 16.8% Margin ▪ Leverage growing leadership position in ▪ European-wide leadership in speciality ▪ Leverage our global
Slide 10: Enabling the supply of medicines in Ireland
Enabling the supply of medicines in Ireland What we do in Uniphar Supply Chain & Retail Supply chain market share Market leadership across Supply Chain & Retail ▪ Leading pharma wholesaler in Ireland with c.54% market share 51% 53% 53% 53% 54% ▪ Retail pharmacy network in Ireland now 430 members1 50
Slide 11: Leader in Irish wholesale and hospital market
Leader in Irish wholesale and hospital market. Longstanding manufacturer relationships, scalable Supported by a network of 430 pharmacies1 digital infrastructure & continued investment in high-tech distribution facilities Revenue Gross Profit Uniphar Wholesale Volume Growth vs Market Volume Growth F
Slide 12: Enabling patient access to specialist medtech
Enabling patient access to specialist medtech What we do in Uniphar Medtech Medium term expansion into southern & central Europe Scaling our Pan-European platform Direct presence ▪ A leading Pan-European medical device distributor and solutions partner, representing 7 of the top 10 global players ac
Slide 13: Sales, marketing and distribution solutions for manufacturers
Sales, marketing and distribution solutions for Building a pan-European service offering to manufacturers support our Medtech partners Revenue Gross Profit Gross Profit Financials €132.5 €53.5m H1'23 H1'24 Gross Profit Reported Organic Growth 3.4% 3.4% €m €20m €40m €60m 2 or more countries 3 or more
Slide 14: Enabling equitable access to medicines worldwide
Enabling equitable access to medicines worldwide What we do in Uniphar Pharma Growing range of capabilities Providing access to specialist and difficult to source medicines ▪ We enable pharma and biotech manufacturers to bring innovative At IPO Developed in-house Partnered medicines to global market
Slide 15: Trusted experts across the product life cycle
Trusted experts across the product life cycle Pre-clinical Clinical Pre-approval Pre-reimbursement Post-reimbursement Off patent Clinical development Product approval Market access Consulting Exclusive access Sales & marketing Licensing On Demand / Global Access Reg & PV Medical Affairs End to end s
Slide 16: Providing access to unlicensed and specialty medicines globally
Providing access to unlicensed and specialty Platform in place to become a global leader in the medicines globally provision of On Demand and Exclusive Access services Revenue Gross Profit Gross Profit Financials €344.2m €57.9m H1'23 Reported Organic H1'24 Gross Profit Growth 20.5% 20.2% €m €20m €40
Slide 17: Financial Review
Financial Review 17
Slide 18: Financial Highlights
Financial Highlights % Growth Gross profit growth across all three Constant (€m) H1’24 H1’23 Reported currency1 Organic2 divisions Revenue 1,367.6 1,239.6 10.3% 10.1% 9.9% Gross profit 206.7 188.0 9.9% 9.7% 7.4% Strong overall EBITDA growth Gross profit margin 15.1% 15.2% 6.3% EBITDA 55.9 52.6 6.3%
Slide 19: Divisional Gross Profit
Divisional Gross Profit Diversified healthcare services business Divisional Composition focused on higher margin opportunities 28% H1’24 H1’23 Growth Organic Gross €’m €’m % Growth % Margin H1’24 €206.7m 46% GP 95.3 88.2 8.1% 3.0% 10.7% 26% 53.5 51.8 3.4% 3.4% 40.4% 25% 57.9 48.0 20.5% 20.2% 16.8% H
Slide 20: Net Bank Debt Analysis
Net Bank Debt1 Analysis €143.6m Net bank debt at 30 Jun 2024 €80.4m Free cashflow (FCF %: 143.8%) FCF conversion adjusted for timing differences is 69.1% YE 2023 EBITDA Net Capex Strategic Acquis. Finance Lease Other2 H1 2024 Working Capex Costs Pay. Capital 20 1. Net bank debt represents the net to
Slide 21: FCF Conversion & Leverage Adjusted FCF
FCF Conversion & Leverage Adjusted FCF Free Cashflow (FCF) H1’24 H1’24 Adj €’m Reported Adjust. Medium term Target EBITDA 55.9 0.0 55.9 60% - 70% Net Working 31.2 (41.8) (10.6) Capital Capital (6.7) 0.0 (6.7) Expenditure We target FCF1 Adjusted FCF Reported free FCF 80.4 38.6 conversion of of 69.1%
Slide 22: Capital Allocation & Investment Case
Capital Allocation & Investment Case 22
Slide 23: Disciplined, balanced investment approach
Disciplined, balanced investment approach Organic Investment Growth Through M&A • Continue to invest in • Fundamental component of infrastructure, digital t Gro compounding growth strategy platforms, strategic capex and en wt h s tm T • Active pipeline of acquisition talent to drive organic growth e
Slide 24: Investment Case
Investment Case Strong track record Experienced Compelling market senior team, tried opportunity in all and tested 3 divisions Progressive Dividend Greater capabilities Each division has an attractive = bigger opportunities competitive moat Clear pathway for success 24
Slide 25: Our strong track record
Our strong track record EBITDA (€m) Margins (%) 116.0 Gross margin EBITDA margin 15.3 4.5 10.8 3.5 58.6 2019 2023 2019 2023 2019 2023 EPS (€ cent)1 Share price (€) 2.65 18.3 9.7 1.15 2019 2023 IPO 2019 Current 25 1. Adjusted EPS has been calculated based on 2023 weighted average shares in issue
Slide 26: Ambition to deliver €200m EBITDA over the medium term
Ambition to deliver €200m EBITDA over the medium term We expect the majority of EBITDA growth to Group guidance | medium term metrics be organic 200 ROCE FCF Dividend Conversion 99 12% - 15% 60% - 70% Dividend Net Bank Debt / EBITDA not to exceed 2022 EBITDA Organic M&A Medium term EBITDA Progressiv
Slide 27: Q&A
Q&A 27
Slide 28: Contact Details
Contact Details Allan Smylie Head of Strategy and Investor Relations +353 (0)1 428 7777 investor.relations@uniphar.ie Q4 PR Public Relations Adviser to Uniphar Iarla Mongey +353 (0)1 475 1444 28
Slide 29: Thank You
Thank You 29
Slide 30: Appendices
Appendices 30
Slide 31: Strategic acquisitions
Transformational Acquisitions Strategic acquisitions 2013 2018 2019 Strong M&A discipline within Strategic Acquisitions the Group complements continued organic growth focus 2014 2015 2015 Acquisition Pipeline Criteria 2017 2017 2018 • Strategic alignment in identified growth segments • Retention of
Slide 32: Uniphar History
Uniphar History Establishing our platform Uniphar’s Heritage Design New Vision Build Differentiated Capabilities Internationalise and Scale 1967 2010 2019 2019 2021 2023 New senior IPO Acquisitions Acquisitions Acquisitions United Pharmaceuticals management team Co-Op Founded appointed (led by Ger R
Slide 33: Summary Management Balance Sheet
Appendices Summary Management Balance Sheet 1 Balance Sheet (€’000) 30 Jun 2024 31 Dec 2023 Goodwill and acquired intangible assets 540,472 537,610 IFRS 16 Right of Use Asset 163,328 131,318 Other non-current assets 137,225 112,699 Total non-current assets 841,026 781,627 Inventory 197,839 184,549 T
Slide 34: Return on Capital Employed
Appendices Return on Capital Employed 12-Month Rolling 30 June (€’000) H1’22 H1’23 H1’24 Numerator Rolling 12 months operating profit 46,616 56,084 71,928 Adjustment for exceptional costs 15,508 16,694 8,205 Amortisation of acquisition related intangibles 2,813 2,921 3,411 Adjusted 12 months operati
Slide 35: Summary Group Financial Information
Appendices Summary Group Financial Information Six months ended 30 June (€’000) H1’24 H1’23 Reported % Growth Revenue 1,367,578 1,239,582 10.3% Gross profit 206,697 187,992 9.9% Overheads & operating income1 (150,796) (135,381) 11.4% EBITDA 55,901 52,611 6.3% Depreciation & amortisation (17,982) (17
Slide 36: EBITDA Reconciliation
Appendices EBITDA Reconciliation EBITDA is earnings before interest, tax, depreciation, amortisation, share-based payments and exceptional items Six months ended 30 June (€’000) H1’24 H1’23 Operating profit pre-exceptional 36,447 34,069 Share-based payments 1,472 1,485 Depreciation 15,078 13,816 Amo
Slide 37: &suniphar
&suniphar